Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;37(5):368-372.
doi: 10.1089/AID.2020.0099. Epub 2021 Feb 2.

Antiretroviral Therapy for HIV-Associated Cutaneous Kaposi's Sarcoma: Clinical, HIV-Related, and Sociodemographic Predictors of Outcome

Affiliations

Antiretroviral Therapy for HIV-Associated Cutaneous Kaposi's Sarcoma: Clinical, HIV-Related, and Sociodemographic Predictors of Outcome

Owen Ngalamika et al. AIDS Res Hum Retroviruses. 2021 May.

Abstract

Kaposi's sarcoma (KS) is an AIDS-defining malignancy that can improve or worsen with antiretroviral therapy (ART). We aimed at identifying clinical, HIV-related, and sociodemographic factors associated with either progression or nonprogression (regression or stable disease) of ART-treated HIV-associated KS in patients with limited cutaneous disease. We conducted a prospective cohort study of ART-treated HIV-associated KS cases. Clinical, HIV-related, and sociodemographic variables were collected at baseline, and patients were followed up to determine treatment outcomes. Cox regression, linear mixed effects model, and Spearman's rank correlation were used for analysis. Half (50%) of the study participants had KS regression or stable disease, whereas the other half (50%) had disease progression during the treatment and follow-up period. Among the data analyzed, presence of KS nodules at baseline (hazard ratio = 5.47; 95% confidence interval = 1.32-22.65; p = .02) was an independent predictor of poor treatment outcome. Progressors and nonprogressors were indistinguishable in the changes they experienced in the HIV plasma viral load and CD4 counts as a result of ART. Even when cutaneous presentation is limited, the presence of nodular morphotype KS lesions should be considered an indicator for combined ART plus chemotherapy. Temporal trends in CD4 counts and HIV viral loads did not correlate with treatment outcome in ART-treated HIV-associated KS.

Keywords: HIV; Kaposi's sarcoma; antiretroviral therapy; outcomes; predictors.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
Kaplan–Meier progression-free survival comparing individuals with KS nodules versus those without KS nodules. The p value is a log-rank test p value. KS, Kaposi's sarcoma. Color images are available online.
FIG. 2.
FIG. 2.
Longitudinal changes in CD4 counts (A) and HIV viral loads (B), and comparisons between progressors and nonprogressors. The lb/ub indicates 95% confidence intervals. On the x-axis are the time points that indicate when the patients presented, irrespective of the actual month/duration. Color images are available online.

References

    1. Semango GP, Charles RM, Swai CI, et al. : Prevalence and associated risk factors for Kaposi's sarcoma among HIV-positive patients in a referral hospital in Northern Tanzania: A retrospective hospital-based study. BMC Cancer 2018;18:1258. - PMC - PubMed
    1. Martin-Carbonero L, Palacios R, Valencia E, et al. : Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008;47:410–417 - PubMed
    1. Li S, Bai L, Dong J, Sun R, Lan K: Kaposi's sarcoma-associated herpesvirus: Epidemiology and molecular biology. Adv Exp Med Biol 2017;1018:91–127 - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424 - PubMed
    1. Chang E, Mapakshi SR, Mbang P, et al. : Impact of protease inhibitors on HIV-associated Kaposi sarcoma incidence: A systematic review. J Acquir Immune Defic Syndr 2018;79:141–148 - PMC - PubMed

Publication types

LinkOut - more resources